Pfizer's tirelessly been working to establish itself as a leading cancer company following the loss of patent protection on its $14-billion per year cholesterol drug, Lipitor, and Besponsa . Subsequent to this approval, the USPTO received patent term restoration applications for BESPONSA (U.S. Patent Nos. 8,153,768; 8,835,611; and 8,747,857) from Wyeth Holdings LLC, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration. In a letter dated April 4, 2018, FDA advised the USPTO that this human biological product had undergone a regulatory review period and that the approval of BESPONSA represented the first permitted commercial . Inotuzumab ozogamicin will be given IV weekly (0.8-0.5 mg/m^2) 3 times per cycle. The comparator arms are: fludarabine, cytarabine and G-CSF or high dose cytarabine or cytarabine and mitoxantrone. The study will start in Jun 12 and is due to complete May 16 (primary outcome data available from Aug 14) .. Explore LivingWith™ To help patients manage life with their diagnosis, Pfizer Oncology created LivingWith™. This free app is designed to help your patients connect with their loved ones, ask for the support they need, remember important information from doctors’ visits, and stay organized, all in one place.. Besponsa is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody (mAb) targeting CD22, a cell surface antigen expressed on cancer cells in almost all B-ALL patients, linked to a cytotoxic agent. When Besponsa binds to the CD22 antigen on B-cells, it is internalized into the cell, where the cytotoxic agent calicheamicin is released to destroy the cell.. Besponsa (inotuzumab ozogamicin), for instance, is an antibody-drug conjugate (ADC) specifically targeting one CSA known as CD22. Novartis AG's CAR-T therapy tisagenlecleucel targets another one, CD19. Other CAR-T therapies in development, though, also target CD22..